Comparison of Clinical and Metabolic Effects of Metformin and Pioglitazone in Polycystic Ovary Syndrome

    Karoon Shahebrahimi, Nasrin Jalilian, Nasrin Bazgir, Mansour Rezaei
    Studysummary In this randomized trial, metformin and pioglitazone both improved certain clinical and metabolic indices in women with PCOS, with pioglitazone showing potential as an alternate treatment for those intolerant to metformin.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome Society The Journal of Clinical Endocrinology & Metabolism · 2010

    Related research 1

    1. Metformin: An Old Medication of New Fashion: Evolving New Molecular Mechanisms and Clinical Implications in Polycystic Ovary Syndrome European journal of endocrinology · 2009